Osteoporosis in the corticosteroid-treated patient with asthma

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 3, 1998, Pages 353-362

  Ledford, Dennis ^a,f   Apter, Andrea ^b   Brenner, Anne Manon ^c   Rubin, Karen ^b   Prestwood, Karen ^b   Frieri, Marianne ^d   Lukert, Barbara ^e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Asthma; Bone density; Corticosteroid; Inhaled corticosteroid; Osteoporosis

Indexed keywords

ALENDRONIC ACID; AMILORIDE; ANTIESTROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; HYDROCHLOROTHIAZIDE; PAMIDRONIC ACID; POTASSIUM SPARING DIURETIC AGENT; PROGESTERONE; RALOXIFENE; TAMOXIFEN; TESTOSTERONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; VITAMIN D;

ASTHMA; BONE DENSITY; BONE REMODELING; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIET SUPPLEMENTATION; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HEALTH CARE COST; HUMAN; HYPERCALCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031704438     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70120-4     Document Type: Article

References (87)

1. Expert Panel Report II: guidelines for the diagnosis and management of asthma. Bethesda (MD): Public Health Service, National Institutes of Health; 1997.
2. Raisz LG. The osteoporosis revolution. Ann Intern Med 1997;126:458-62.
3. American College of Rheumatology Task Force on Osteoporosis guidelines. Recommendation for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
4. Consensus Development Conference on Osteoporosis. Hong Kong, 1-2 April, 1993. Am J Med 1993;95:1S-78S.
5. Melton LJ III. Epidemiology of vertebral fractures in women. Am J Epidemiol 1989;129:1000-11.
6. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178-208.
7. Cooper C. The crippling consequences of fractures and their input on quality of life. Am J Med 1997;103:12-9S.
8. Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine 1990;69:137-49.
9. Hawker GA. The epidemiology of osteoporosis. J Rheumatol 1996;23(suppl 45):2-5.
10. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a worldwide projection. Osteoporos Int 1992;2:285-9.
11. Melton LJ. Hip fractures: a world wide problem today and tomorrow. Bone 1993;14:S1-8.
12. Riggs BC, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, et al. Changes in bone mineral density of the proximal femur and spine with aging. J Clin Invest 1982;70:716-23.
13. Scott JC. Epidemiology of osteoporosis. J Clin Rheumatol 1997;3:S9-13.
14. Kelly P, Eisman J, Sambrook P. Interaction of genetic and environmental influences on peak bone density. Osteoporos Int 1990;1:14-22.
15. Orwall E. Osteoporosis in men. In: Marcus R, Feldman D, Kelsey J, editors. San Diego: Academic Press; 1996.
16. Eisman JA, Morrison NA, Kelly PJ, Sambrook PN, Howard G, Qi J, et al. Genetics of osteoporosis and Vitamin D receptor alleles. Calcif Tissue Int 1995;56(suppl 1):S48-9.
17. Uitterlinden AG, Burger H, Huang Q, Yue F, McGuigan FE, Grant SF, et al. Relation of alleles of the collagen type IX 1 gene to bone density and the risk of osteoporotic fractures in post-menopausal women. N Engl J Med 1998;338:1016-21.
18. Melton LJ. Epidemiology of age-related fractures. In: Avioli L, editor. The osteoporotic syndrome: detection, prevention, treatment. New York: Wiley-Liss; 1993. pp. 17-38.
19. Bauer RL. Ethnic differences in hip fracture: a reduced incidence in Mexican Americans. Am J Epidemiol 1988;127:145-9.
20. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
21. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
22. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate-day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1994;25:615-20.
23. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
24. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995;22:1055-9.
25. Gennari C. Glucocorticoids and bone. In: Peck WA, editor. Bone and mineral research. Amsterdam: Elsevier; 1985. pp. 213-32.
26. LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39-51.
27. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994;20:630-51.
28. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
29. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997;52(suppl 39):1-34.
30. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5.
31. Toogood JH, Baskerville J, Markov AE, Hodsman AB, Fraher LJ, Jennings B, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-66.
32. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995;96:571-9.
33. Faulkner KG, Herie NE, Gaither KW. Two-year prospective study of inhaled fluticasone propionate: effects on bone mineral density [abstract]. J Bone Miner Res 1997;12:S142.
34. Herrala J, Puolijoki H, Impivaara O, Liippo K, Tala E, Nieminen MM. Bone mineral density in asthmatic women on high-dose inhaled beclomethasone. Bone 1994;15:621-3.
35. Lukert BP, Higgins JC, Stoskopf MM. Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J Clin Endocrinol Metab 1986;62:1056-8.
36. Simons FER and the Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997;337:1659-65.
37. Rachelefsky GS, Chervinsky P, Meltzer EO, Morris RM, Seltzer JM, Skoner DP, et al. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray [Vancenase AQ (VNS)] on long-term growth in children [abstract]. J Allergy Clin Immunol 1998;101:S236.
38. Knutsson U, Stierna P, Marcus C, Carlstedt-Duke J, Carlstrom K, Bronnegard M. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol 1995;144:301-10.
39. World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. WHO Technical Report Series. 1994;843:5-6.
40. Johnston CC Jr, Slemenda CW, Melton LJ III. Clinical use of bone densitometry. N Engl J Med 1991;324:1105-8.
41. Saito JK, Davis JW, Wasnich RD, Ross PD. Users of low dose glucocorticoids have increased bone loss rates, a longitudinal study. Calcif Tissue Int 1995;57:115-9.
42. Boulet LP, Giguere MC, Milot J, Brown J. Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immunol 1994;94:796-803.
43. NIH Consensus Conference: Optimal calcium intake. JAMA 1994;272:1942-8.
44. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. The effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993;328:460-4.
45. Schwartzman MS, Franck WA. Vitamin D toxicity complicating the treatment of senile, post-menopausal, glucocorticoid-induced osteoporosis. Am J Med 1987;82:224-30.
46. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Stat M, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
47. LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990;22:286-90.
48. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces gluco-corticoid induced bone loss. J Bone Miner Res 1992;7:1063-9.
49. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994;37:1499-505.
50. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156:1173-7.
51. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
52. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
53. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheum 1994;33:348-50.
54. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in post-menopausal women. Am J Med 1995;98:459-63.
55. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidine)-1, 1-bisphosphonate (APD). Lancet 1988;1:143-6.
56. Luengo M, Picado C, Del Rio L, Guañabens N, Montserrat JM, Setoain J. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma: a one-year follow-up study. Am Rev Respir Dis 1990;142:104.
57. Kenny AM, Prestwood KM, Pilbeam CC, Raisz LG. The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 1995;80:3287-91.
58. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci 1995;761:355-60.
59. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
60. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, et al. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996;153:1739-48.
61. Raloxifene for postmenopausal osteoporosis. Med Lett Drugs Ther 1998;40:29-30.
62. Norman ME. Juvenile osteoporosis. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 3rd ed. Philadelphia: Lippincott-Raven; 1996. pp. 275-82.
63. Warady BD, Lindsley CB, Robinson RG, Lukert BP. Effects of nutritional supplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy. J Rheumatol 1994;21:530-5.
64. Slemenda CW, Reister TK, Hui SL, Miller JZX, Christian JC, Johnston CC. Influences on skeletal maturation in children and adolescents: evidence for varying effects of sexual maturation and physical activity. J Pediatr 1994;125:201-7.
65. Seeman E, Tsalamandris C, Formica C, Hopper JL, McKay J. Reduced femoral neck bone density in daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis. J Bone Miner Res 1994;9:739-43.
66. Ott SM. Bone density in adolescents. N Engl J Med 1991;325:1647.
67. Reimer LG, Morris HG, Ellis EF. Growth of asthmatic children during treatment with alternate-day steroids. J Allergy Clin Immunol 1975;55:224-31.
68. Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglas R, et al. Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J Pediatr 1993;122:219-26.
69. Baraldi E, Bollini MC, DeMarchi A, Zacchello F. Effect of beclomethasone dipropionate on bone mineral content assessed by x-ray densitometry in asthmatic children: a longitudinal evaluation. Eur Respir J 1994;7:710-4.
70. Kinberg KA, Hopp RJ, Biven RE, Gallagher JC. Bone mineral density in normal and asthmatic children. J Allergy Clin Immunol 1994;94:490-7.
71. Hopp RJ, Degan JA, Biven RE, Kinberg GC. Longitudinal assessment of bone mineral density in children with chronic asthma. Ann Allergy Asthma Immunol 1995;75:143-8.
72. Toogood JH, Jennings B, Hodsman AB, Baskerville JC, Fraher LJ. Effects of dose and dosing schedule of inhaled budesonide on bone mover. J Allergy Clin Immunol 1991;88:572-80.
73. Martinelli LC, Bertoldo F, Gaspari E, et al. Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma. Am J Respir Crit Care Med 1996;153:232-6.
74. Matkovic V. Editorial: skeletal development and bone turnover revisited. J Clin Endocrinol Metabolism 1996;81:2013-6.
75. Ott SM. Editorial: attainment of peak bone mass. J Clin Endocrin Metab 1990;71:1083-8.
76. Rubin K, Schirduan V, Gendreau P, Sarfarazi M, Mendola R, Dalsky G. Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of puberty. J Pediatr 1993;123:863-70.
77. Johnston CC, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, et al. Calcium supplementation with increase in bone mineral density in children. N Engl J Med 1992;327:82-7.
78. Bachrach LK, Guido D, Katzman D, Liff IF, Marcus R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics 1990;86:440-7.
79. Abrams SA, Silber TJ, Esteban NV, Viera NE, Stuff JE, Myers R,et al. Mineral balance and bone turnover in adolescent girls with anorexia nervosa. J Pediatr 1993;123:326-31.
80. Lonzer MD, Imrie R, Rogers D, Worley D, Licata A, Secic M. Effects of heredity, age, weight, puberty, activity, and calcium intake on bone mineral density in children. Clin Pediatr 1996;35:185-9.
81. Hergenroeder AC. Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 1995;126:683-9.
82. White CM, Hergenroeder AC, Klish WJ. Bone mineral density in 15-21 year old eumenorrheic and amenorrheic subjects. Am J Dis Child 1992;146:31-5.
83. Thomas KA, Cook SD, Beenett JT. Femoral neck and lumbar spine mineral densities in a normal population 3-20 years of age J Pediatr Orthop 1991;11:48-58.
84. Kriepe RE. Bone mineral density in adolescents. Pediatr Ann 1995;24:308-15.
85. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79:780-5.
86. Delmas PD. Clinical use of biochemical markers of bone remodeling in osteoporosis. Bone 1992;13:517-21.
87. Hanson DA, Weis M-AE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen crosslinked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.